Recombinant Human Erythropoietin Increasing Hemoglobin Level and Reducing Blood Transfusion in Femoral Fracture Patients : A Double-Blinded Randomized Controlled Trial Study

Recombinant human erythropoietin increasing hemoglobin level and reducing blood transfusion in femoral fracture patients, a randomized controlled trial study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230117005

Enrollment

Registered

2023-01-17

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemoglobin loss in femoral fracture patient blood transfusion hemoglobin level

Interventions

Single dose 40000 IU of EPO SC on admit date,0.9% nss 1 ml SC

Experimental Drug,Placebo Comparator Other

EPO,0.9% NSS

Eligibility

Sex/Gender

All

Age

15 Years to 80 Years

Inclusion criteria

Inclusion criteria: Femoral fracture patients age 15 - 80 years old who underwent surgical intervention

Exclusion criteria

Exclusion criteria: 1. patients with hemoglobin less than 9 g/dL, greater than 16 g/dL, 2.on antiplatelets drugs, 3.known case bone marrow disease etc thalassemia, myelodysplastic syndrome, multiple myeloma 4.Chronic kidney disease, 5.Allergy if EPO, 6.Contraindicated for EPO, 7.Severe traumatic brain injury

Design outcomes

Primary

Measure	Time frame
Hemoglobin level 2 weeks follow up Blood for hemoglobin level	—

Secondary

Measure	Time frame
Reticulocyte count During admit and 2 weeks follow up Blood for Reticulocyte count	—

Countries

Thailand

Contacts

Public ContactRudeetip Smithsarakarn

Faculty of Medicine Vajira Hospital, Navamindradhiraj University.

Rudeetip@nmu.ac.th022443376

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026